Cost-Effectiveness in the Surgical Care of Renal Cell Carcinoma

被引：0
|
作者：
不详
机构：
来源：
CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY | 2018年 / 16卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：177 / 179
页数：3
相关论文
共 50 条
  • [21] Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom
    Amdahl, Jordan
    Diaz, Jose
    Sharma, Arati
    Park, Jinhee
    Chandiwana, David
    Delea, Thomas E.
    PLOS ONE, 2017, 12 (06):
  • [22] Cost-Effectiveness of Sorafenib for Second-Line Treatment of Advanced Renal Cell Carcinoma
    Hoyle, Martin
    Green, Colin
    Thompson-Coon, Jo
    Liu, Zulian
    Welch, Karen
    Moxham, Tiffany
    Stein, Ken
    VALUE IN HEALTH, 2010, 13 (01) : 55 - 60
  • [23] Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States
    Charles McCrea
    Sukhvinder Johal
    Shuo Yang
    Justin Doan
    Experimental Hematology & Oncology, 7
  • [24] Cost-Effectiveness of the First Line Treatment Options For Metastatic Renal Cell Carcinoma in India
    Gupta, Dharna
    Singh, Ashish
    Gupta, Nidhi
    Mehra, Nikita
    Bahuguna, Pankaj
    Aggarwal, Vipul
    Krishnamurthy, Manjunath Nookala
    Roy, Partha Sarathi
    Malhotra, Pankaj
    Gupta, Sudeep
    Kumar, Lalit
    Kataki, Amal
    Prinja, Shankar
    JCO GLOBAL ONCOLOGY, 2023, 9 : e2200246
  • [25] Cost-Effectiveness of Second-Line Treatments for Metastatic Renal-Cell Carcinoma
    Giuliani, Jacopo
    Bonetti, Andrea
    CLINICAL GENITOURINARY CANCER, 2019, 17 (02) : E258 - E262
  • [26] Cost-effectiveness of nivolumab in patients with advanced renal cell carcinoma treated in the United States
    McCrea, Charles
    Johal, Sukhvinder
    Yang, Shuo
    Doan, Justin
    EXPERIMENTAL HEMATOLOGY & ONCOLOGY, 2018, 7
  • [27] Economic evaluation of sorafenib versus best supportive care in advanced renal cell carcinoma: An updated cost-effectiveness analysis
    Gao, X.
    Shah, S.
    Reddy, P.
    Gondek, K.
    Pashos, C. L.
    VALUE IN HEALTH, 2008, 11 (03) : A61 - A61
  • [28] COST-EFFECTIVENESS ANALYSES OF IMMUNE CHECKPOINT INHIBITORS IN RENAL CELL CARCINOMA: A SCOPING REVIEW
    Tugwete, C.
    Wang, X.
    Le, N.
    Dang, Q. T.
    Park, C.
    VALUE IN HEALTH, 2024, 27 (06) : S117 - S117
  • [29] COST-EFFECTIVENESS ANALYSIS OF TEMSIROLIMUS IN PATIENTS WITH POOR RISK RENAL-CELL CARCINOMA
    Kan, H. C.
    Pwu, R. F.
    VALUE IN HEALTH, 2012, 15 (07) : A656 - A656
  • [30] A DISCRETE EVENT SIMULATION MODEL FOR RENAL CELL CARCINOMA FOR USE IN A COST-EFFECTIVENESS ANALYSIS
    Dansk, V
    Treharne, C.
    Santi, R.
    Malcolm, B.
    Johal, S.
    VALUE IN HEALTH, 2017, 20 (09) : A748 - A748
12345